Ed Miseta

Ed Miseta



Ed Miseta is chief editor for the website Clinical Leader, executive editor for Life Science Leader magazine, conference chair for Clinical Leader Forum, and host of Clinical Leader Live. Ed studied Business Economics at The Pennsylvania State University and also holds a Master’s degree in Business Administration. Ed has been a writer for more than 12 years and has been covering clinical research since January 2013. Ed spent 10 years in banking and investments and also taught economics at Penn State for 8 years. In his current position, Ed interviews clinical executives from pharmaceutical and biotech companies and shares their insights with readers. His primary focus is on best practices, challenges faced and overcome, clinical trends, partnering, and implementing new technologies. He has also moderated numerous speaker panels at industry conferences and trade shows.

ARTICLES BY ED MISETA

  • The Patient Perspective – My Experience In A Clinical Trial
    5/13/2021

    After years of following the evolving landscape of ACHM therapeutic development, Alison Lynch participated in one of the first clinical trials for a potential treatment for this incurable disease. In celebration of Clinical Trials Day on May 20, 2021, Alison spoke with Clinical Leader to share her perspectives on trial participation and the necessity to look at the big picture.
  • DIA 2021 Promises Stellar Panels And An Improved Virtual Experience
    5/7/2021

    The emergence of the COVID pandemic in 2019 hit a lot of organizations in the R&D and clinical space by surprise. The companies and organizations that convene stakeholders were no exception. One of those organizations was DIA. When shutdowns began to sweep across the globe in March, DIA’s Global Annual Meeting, which brings together thousands of attendees from around the world, was just 90 days away.
  • The Benefits Of A Functional Service Provider (FSP) Model In Uncertain Times
    5/3/2021

    Contract research outsourcing can be a challenging endeavor even in the best of times. Simply selecting the right model can be a difficult chore, and then there is the task of selecting the right partners, preparing contracts, and conducting oversight. When operating in uncertain times, the process becomes significantly more difficult. 
  • How Machine Learning Will Eliminate Failures In Clinical Trials
    4/28/2021

    AI’s full potential will not be realized for at least another decade, but machine learning (a component of AI) is a technology that is available now. Still, judging by the amount of content and webinars I see on this topic, it seems many in the industry are still trying to understand how it will be used and why it may be a game changer when it comes to trial conduct.
  • How Patient Voice Created A More Immersive Trial Experience At Janssen
    4/26/2021

    Janssen has been attempting to develop a streamlined clinical trial experience for patients. Kafayat Babajide, associate director of patient portals for Janssen, spoke at the 2021 SCOPE conference and described the company’s goal as having a one-stop shop for patients. The one-stop shop now has a name, which is My Trial Community.
  • UCB And Microsoft Collaborate On AI For Therapeutics R&D
    4/19/2021

    UCB and Microsoft have worked together previously, collaborating on IT solutions in drug discovery and development. Now the two companies have taken that collaboration a step further with an expansion that will allow UCB to better discover and develop medicines for patients living with severe diseases. 
  • Thermo Fisher To Acquire PPD
    4/15/2021

    In an effort to create greater customer and shareholder value, Thermo Fisher Scientific has announced plans to acquire clinical research organization PPD for a cash purchase price of $17.4 billion. The purchase will also include the assumption of approximately $3.5 billion of net debt.
  • Janssen’s Innovation Strategy To Target Immune-Mediated Disease
    4/15/2021

    Tom Cavanaugh believes there is a tremendous unmet need in the industry for treatments that target patients suffering from immune-mediated diseases. Cavanaugh, the president of immunology for Janssen in the U.S., notes that unmet need is a primary factor that drives the work he and his team perform. 
  • From Medical Researcher To CEO
    3/31/2021

    Yan Chen used her industry experience and interest in immunology to start Elpis Biopharmaceuticals, a company hoping to find cures for difficult-to-treat cancers.
  • Three Things Pharma Must Do To Advance Patient Diversity
    3/23/2021

    One of the biggest challenges drug developers will face in 2021 and beyond is the inclusion of more minority patients in clinical trials. The COVID pandemic has put a spotlight on diversity, with a disproportionate number of African Americans contracting the virus while still being underrepresented in treatment and vaccine trials.
More From Ed Miseta